Key result
Vasoactive intestinal peptide relaxes preconstricted human coronary segments by ~74% via specific receptors.
Why the study?
The role of vasoactive intestinal peptide (VIP) in the regulation of coronary vascular tone and its receptor distribution in human coronary arteries was unclear.
Population
97 segments of isolated human coronary arteries from 23 patients undergoing cardiac transplantation
Comparison
VIP vs specific receptor antagonist [4CI-D-Phe6, Leu17] VIP, atropine, indomethacin, and endothelium removal
Design
Preclinical study of isolated human coronary artery segments
Authors
Loading...
Suggests VIP modulates human coronary tone; leaves open its role in CAD or therapeutic targeting.
Absolute Event Rate: 73.8% vs 38.9%
p-value: p=<0.001
Vasoactive intestinal peptide elicits endothelium-independent vasodilatation of human coronary arteries by acting on specific receptors on smooth muscle, suggesting a role in regulating coronary tone.
Luu et al. (1992) studied Patients undergoing cardiac transplantation (n=23). Vasoactive intestinal peptide (VIP) vs. Specific receptor antagonist [4CI-D-Phe6, Leu17] VIP was evaluated on Maximum relaxation of preconstricted coronary segments (p=<0.001). Vasoactive intestinal peptide relaxed preconstricted human coronary segments (maximum response 73.8%), which was significantly reduced to 38.9% by a specific receptor antagonist (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: